ANNAPOLIS, Md., Aug. 5 /PRNewswire-FirstCall/ -- PharmAthene, Inc. a biodefense company developing medical countermeasures against biological and chemical threats, announced today that its financial results for the second quarter of 2008 will be released on Tuesday, August 12, 2008.
PharmAthene management will be hosting a conference call to discuss its second quarter 2008 financial results. The call is scheduled to begin at 4:30 p.m. Eastern Time on Tuesday, August 12, 2008 and will last approximately 45 minutes.
The dial-in number within the United States is 800-706-7741. The dial-in number for international callers is 617-614-3471. The participant passcode is 48062719.
A replay of the conference call will be available for 30 days, beginning at approximately 6:30 p.m. Eastern Time on August 12, 2008 until approximately 11:50 p.m. Eastern Time September 9, 2008. The dial-in number from within the United States is 888-286-8010. For international callers, the dial-in number is 617-801-6888. The participant passcode is 76313724.
The conference call will also be webcast and can be accessed from the company's website at www.pharmathene.com. A link to the webcast may be found under the Investor Relations section of the website. The webcast will be available for 30 days, or until approximately September 9, 2008.
About PharmAthene, Inc.
PharmAthene was formed to meet the critical needs of the United States and its allies by developing and commercializing medical countermeasures against biological and chemical weapons. PharmAthene's lead product development programs include (1) SparVax(TM) -- a second generation recombinant protective antigen (rPA) anthrax vaccine, (2) Valortim(TM) -- a fully human monoclonal antibody for the prevention and treatment of anthrax infection, (3) Protexia(R) -- a novel bioscavenger for the prevention and treatment of morbidity and mortality associated with exposure to chemical nerve agents, (4) RypVax(TM) -- a recombinant dual antigen vaccine for plague, and (5) a third generation rPA anthrax vaccine. For more information about PharmAthene, please visit www.PharmAthene.com.
CONTACT: Stacey Jurchison for PharmAthene, Inc., +1-410-269-2610,
JurchisonS@PharmAthene.com
Web site: http://www.pharmathene.com/
